TiGenix obtains FDA''s endorsement through Special Protocol Assessment for its
Cx601 Phase III registration trial in the US
Leuven (BELGIUM) - August 7, 2015 - TiGenix NV (Euronext Brussels: TIG), an
advanced biopharmaceutical company focused on developing and ...
↧